Ignite Creation Date:
2025-12-26 @ 11:10 AM
Ignite Modification Date:
2025-12-26 @ 11:10 AM
Study NCT ID:
NCT04583228
Status:
COMPLETED
Last Update Posted:
2022-04-01
First Post:
2020-09-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
Sponsor:
Hengenix Biotech Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-08
Start Date Type:
ACTUAL
Primary Completion Date:
2021-07-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-07-20
Completion Date Type:
ACTUAL
First Submit Date:
2020-09-25
First Submit QC Date:
None
Study First Post Date:
2020-10-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-03-20
Last Update Post Date:
2022-04-01
Last Update Post Date Type:
ACTUAL